 The purpose of this study is to determine the safety and efficacy of two study products in children with atopic dermatitis. One of the study products formulation 609580 20 is not commercially available outside of clinical trials such as this one. The other study product formulation 609209 has been approved in Canada and is currently available commercially under the trade name Lipikar Baume. 